The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open‐label extension analysis
Abstract
Objective: To determine the safety and efficacy of additional courses of rituximab in patients with rheumatoid arthritis (RA). Methods: An open‐label extension analysis of RA patients previously treated with rituximab was conducted. Patients who had participated in any of 3 double‐blind trials were eligible for additional courses (2 infusions of 1,000 mg given 2 weeks apart) if they exhibited a swollen joint count and tender joint count of ≥8 with ≥16 weeks elapsing after the previous course. Safety was assessed in patients receiving all or a portion of a rituximab course. Efficacy was assessed 24 weeks after each course, using the American College of Rheumatology 20% criteria for improvement (ACR20), ACR50, ACR70, European League Against Rheumatism (EULAR) response criteria, Disease Activity Score in 28 joints, the disability index of the Health Assessment Questionnaire, and Short Form 36 scores, stratified according to prior tumor necrosis factor (TNF) inhibitor exposure. Results: A total of 1,039 patients received ≥1 course of rituximab. Of these, 570 received 2 courses, 191 received 3 courses, and 40 received 4 courses, for a total of 1,669 patient‐years. Irrespective of prior TNF inhibitor exposure, ACR20 responses were comparable at week 24 after course 1 and at week 24 after course 2 (65% versus 72%), as were ACR50 and ACR70 responses. EULAR moderate/good responses were also comparable in course 2 relative to course 1 (88% versus 79%), with EULAR remission occurring in a 2‐fold higher proportion of patients after course 2 than after course 1 (13% versus 6%). The most common adverse events, which were mild‐to‐moderate acute infusion‐related events, decreased with each course. The serious infection rate after course 1 (5.1 per 100 patient‐years) remained stable through additional courses. The proportion of patients with circulating IgM and IgG levels below the lower limit of normal (LLN) increased with subsequent courses; however, serious infection rates in these patients (5.6 per 100 patient‐years in patients with low IgM levels and 4.8 per 100 patient‐years in patients with low IgG levels were comparable with those in patients with immunoglobulin levels above the LLN (4.7 per 100 patient‐years). Patients with human antichimeric antibody (9.2%) did not exhibit decreasing efficacy or present additional safety concerns. Conclusion: These findings indicate that patients treated with repeated courses of rituximab have sustained clinical responses with no new adverse events.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Measurement of patient outcome in arthritis
Fries, J. F., Spitz, P., Kraines, R. G., & Holman, H. R. (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230202 · Cited by 4,382
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Self-citationAmerican college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Self-citationInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Self-citationCytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
Choy, E. H. S., & Panayi, G. S. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103223441207 · Cited by 2,249
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Self-citationDepletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Self-citationCohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Self-citationvan Gestel, A. M., Prevoo, M. L. L., van't Hof, M. A., van Rijswijk, M. H., van de Putte, L. B. A., & van Riel, P. L. C. M. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390105 · Cited by 1,572
INFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Ipsky, P. E. E. L., Illiam, E. W., Urst, D. A. E. F., Reedveld, C. B., Oachim, J., Alden, R. K., Osef, J., Molen, S. S., Eisman, M. I. W., Mery, P. A. E., et al. (2000) · Cited by 1,155
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
Self-citationDixon, W. G., Watson, K., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21978 · Cited by 751
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
New Drugs for Rheumatoid Arthritis
Olsen, N. J., & Stein, C. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032906 · Cited by 626
T Cell Activation in Rheumatoid Synovium Is B Cell Dependent
Takemura, S., Klimiuk, P. A., Braun, A., Goronzy, J. J., & Weyand, C. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4710 · Cited by 536
Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
Edwards, J. C. W., & Cambridge, G. (2001) · Rheumatology · doi:10.1093/rheumatology/40.2.205 · Cited by 523
(1993) · PubMed · Cited by 469
Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis
Isomäki, H. A., Hakulinen, T., & Joutsenlahti, U. (1978) · Journal of Chronic Diseases · doi:10.1016/0021-9681(78)90071-1 · Cited by 433
Rheumatoid arthritis and cancer risk
Mellemkjær, L., Linet, M. S., Gridley, G., Frisch, M., Møller, H., & Olsen, J. H. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00210-9 · Cited by 383
Keystone, E. C., Schiff, M. H., Kremer, J. M., Kafka, S., Lovy, M., DeVries, T., & Burge, D. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20019 · Cited by 284
Self-citationAnderson, D. R., Grillo-López, A., Varns, C., Chambers, K. S., & Hanna, N. (1997) · Biochemical Society Transactions · doi:10.1042/bst0250705 · Cited by 248
Burmester, G. R., Xavier Mariette, A., Montecucco, C., Sáez, I. M., Malaise, M., Tzioufas, A. G., Bijlsma, J. W. J., Unnebrink, K., Kary, S., & Küpper, H. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066761 · Cited by 202
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.
Moreland, L. W., Cohen, S., Baumgartner, S. W., et al. (2001) · PubMed · Cited by 201
Do self‐perpetuating B lymphocytes drive human autoimmune disease?
Edwards, Cambridge, & Abrahams (1999) · Immunology · doi:10.1046/j.1365-2567.1999.00772.x · Cited by 174
The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets
Dörner, T., & Burmester, G. R. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200305000-00011 · Cited by 164
Metlay, J. P., Puré, E., & Steinman, R. M. (1989) · Advances in Immunology · doi:10.1016/s0065-2776(08)60662-8 · Cited by 159
Patient-reported outcomes and their role in the assessment of rheumatoid arthritis
Lubeck, D. P. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422001-00004 · Cited by 123
Moreland, L. W., Weinblatt, M. E., Keystone, E. C., Kremer, J. M., Martin, R. W., Schiff, M. H., Whitmore, J. B., & White, B. (2006) · PubMed · Cited by 117
Self-citationMcInnes, I. B. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70207-6 · Cited by 47
Pistoia, V., & Corcione, A. (1995) · Stem Cells · doi:10.1002/stem.5530130506 · Cited by 24
Sell, S., & Max, E. E. (2001) · doi:10.1128/9781555818012.ch4 · Cited by 6
Cited by
Adverse effects of biologics: a network meta-analysis and Cochrane overview
Singh, J. A., Wells, G. A., Christensen, R., Tanjong Ghogomu, E., Maxwell, L. J., MacDonald, J. K., Filippini, G., Skoetz, N., Francis, D. K., Lopes, L. C., et al. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008794.pub2 · Cited by 823
Klareskog, L., Catrina, A. I., & Paget, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60008-8 · Cited by 787
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Self-citationvan Assen, S., Agmon-Levin, N., Elkayam, O., Cervera, R., Doran, M. F., Dougados, M., Emery, P., Geborek, P., Ioannidis, J. P. A., Jayne, D. R. W., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.137216 · Cited by 630
Self-citationKhosroshahi, A., Bloch, D. B., Deshpande, V., & Stone, J. H. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27435 · Cited by 522
Metadata
- Authors
- Keystone, E., Fleischmann, R., Emery, P., Furst, D. E., van Vollenhoven, R., Bathon, J., Dougados, M., Baldassare, A., Ferraccioli, G., Chubick, A., Udell, J., Cravets, M. W., Agarwal, S., Cooper, S., & Magrini, F.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2007-11-29
- Volume
- 56
- Issue
- 12
- Pages
- 3896-3908
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2077882848
- Cited by
- 337
- References
- 36
- FWCI
- 23.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.